Scientific Literature

Limitations of the Method

The results obtained must always be interpreted in combination with the patient’s complete clinical picture and dietary changes must be made in consultation with a qualified health professional. The IgG concentrations determined using this test system make it possible to infer information about the degree of sensitization of the patient to the food antigens or mixtures tested. They cannot be used to derive a relationship between the determined IgG concentration and serious clinical symptoms. False positive test results may be produced by cross-reactivity of the antigens tested with the epitopes of other antigens.

A number of allergy associations do not support IgG testing as a means to diagnose food intolerances or hypersensitivities. However, a growing number of publications and client experience support that elimination diets based on circulating IgG antibodies result in improved symptoms. A subset of these peer reviewed published papers are listed below:

Scientific Literature

1. Bentz S, Hausmann M, Piberger H, Kellermeier S, Paul S, Held L, Falk W, Obermeier F, Fried M, Scholmerich J, Rogler G.
Clinical Relevance of IgG Antibodies against Food Antigens in Crohns Disease: A double-Blind Cross-Over Diet Intervention Study. (2010) Digestion; 252-264.

2. Atkinson W, Sheldon TA, Shaath N, Whorewall PJ.
Food elimination based on IgG antibodies in irritiable bowel syndrome: a randomised controlled trial. (2004) Gut; 53: 1459-1464.

3. Wilders-Truschnig M, Mangge H, Lieners C, Gruber HJ, Mayer C, Marz W
IgG antibodies against food antigens are correlated with inflammation and Intima media thickness in obese juveniles. (2007) exp Clin Endocrinol Diabetes; 241-245.

4. Mullin GE, Swift KM, Lipski L, Turnball LK, Rampertab SD.
Testing for Food Reactions: The Good, the Bad and the Ugly. (2010) Nutrition in Clinical Practice; 25:192-198.

5. Alpay K, Ertas M, Orhan EK, Ustay DK, Lieners C,  Baykan B
Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. (2010) Cephalgia 1-9.

All names, illustrations, graphics, tables, trademarks and other materials related to ImuPro shown on the page are either owned by or licensed to R-Biopharm AG, Germany and are protected by copyright